NCT01167569

Brief Summary

It has been shown that the stress that occurs during cardiac surgery leads to early decrease of many of the body's resources such as Vitamin C (ascorbic acid) which may contribute to complications after surgery. This study will investigate the effects of high doses of intravenous (IV) Vitamin C on the outcome and complications after cardiac surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
57

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Oct 2007

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2007

Completed
2.4 years until next milestone

First Submitted

Initial submission to the registry

February 5, 2010

Completed
6 months until next milestone

First Posted

Study publicly available on registry

July 22, 2010

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2013

Completed
7.6 years until next milestone

Results Posted

Study results publicly available

October 19, 2020

Completed
Last Updated

October 19, 2020

Status Verified

September 1, 2020

Enrollment Period

5.5 years

First QC Date

February 5, 2010

Results QC Date

January 4, 2017

Last Update Submit

September 24, 2020

Conditions

Keywords

Free RadicalsAscorbic AcidCardiac SurgeryPrevention of Reperfusion Injury

Outcome Measures

Primary Outcomes (1)

  • Mortality

    Number of patients who expire within 30 days of their surgery (both in patients and discharged patients)

    30 days

Secondary Outcomes (1)

  • Renal Insufficiency

    hospital discharge

Study Arms (2)

A-Ascorbic Acid (Vitamin C)

ACTIVE COMPARATOR

Ascorbic Acid (Vitamin C) 10mg/kg x 2 in the operating room followed by Ascorbic Acid (Vitamin C) 5mg/kg every 4 hours x 48 hours.

Drug: Ascorbic Acid

B-5% Dextrose Water or Normal Saline

PLACEBO COMPARATOR

5% Dextrose Water or Normal Saline (placebo) x 2 in the operating room followed by 5 % Dextrose Water or NS (placebo) every 4 hours X 48 hours.

Other: 5 % Dextrose Water or Normal Saline

Interventions

Ascorbic Acid/Placebo 10mg/kg body weight X2 in Operating Room followed by Ascorbic Acid/Placebo 5mg/kg x 48 hours.

Also known as: Vitamin C
A-Ascorbic Acid (Vitamin C)

100 ml D5W or NS X 2 in operating room and then every 4 hours for 48 hours.

Also known as: D5W or NS
B-5% Dextrose Water or Normal Saline

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients 18 years or older undergoing elective or urgent (prior to hospital discharge) cardiac surgery.

You may not qualify if:

  • History of renal insufficiency, nephrolithiasis, G6PD (glucose-6-phosphate dehydrogenase deficiency) or the chronic use of steroids.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Robert Wood Johnson University Hospital

New Brunswick, New Jersey, 08901, United States

Location

MeSH Terms

Conditions

Reperfusion Injury

Interventions

Ascorbic AcidSaline Solution

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Sugar AcidsAcids, AcyclicCarboxylic AcidsOrganic ChemicalsHydroxy AcidsCarbohydratesCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Results Point of Contact

Title
Alan Spotnitz, MD
Organization
Rutgers RWJMS

Study Officials

  • Alan Spotnitz

    Rutgers RWJMS

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 5, 2010

First Posted

July 22, 2010

Study Start

October 1, 2007

Primary Completion

April 1, 2013

Study Completion

April 1, 2013

Last Updated

October 19, 2020

Results First Posted

October 19, 2020

Record last verified: 2020-09

Data Sharing

IPD Sharing
Will not share

Locations